Supreme Court Won't Hear CareDx Appeal in Natera Ad Dispute
The U.S. Supreme Court rejected CareDx's appeal in its false-advertising clash with Natera, leaving a lower court ruling intact.
The U.S. Supreme Court has declined to take up CareDx's appeal in its false-advertising fight with Natera (NTRA), effectively closing the door on CareDx's bid to overturn an earlier ruling. When the high court refuses to hear a case, the decision below stands — and that's bad news for CareDx.
For traders watching NTRA, this is a meaningful development. Natera's kidney transplant rejection test, Prospera, has been at the center of a heated commercial battle. A Supreme Court pass means Natera keeps whatever legal ground it already won in the lower courts, removing a major overhang that could have forced the company to revisit its marketing claims.
Read more BoE's Mann: Fewer Rate Hike Bets Are Why She'd Hike More →
CareDx had pushed hard for the Supreme Court to weigh in, signaling how much was at stake commercially. False-advertising disputes in the diagnostics space aren't just legal noise — they directly shape which tests doctors order and how aggressively companies can tout clinical advantages. Losing that platform matters to the bottom line.
For Natera bulls, this is a clean win that lets management stay focused on growth rather than litigation risk. For CareDx, the path forward just got narrower. If you're trading either name, the legal calendar just got a lot simpler — and Natera holds the edge.
Continue reading at Yahoo Finance
